Stockscreener 앱 받기
7.30
1.18%
0.085
시간 외 거래:
7.30
전일 마감가:
$7.215
열려 있는:
$7.06
하루 거래량:
1.63M
Relative Volume:
1.00
시가총액:
$1.16B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-5.4074
EPS:
-1.35
순현금흐름:
$-90.59M
1주 성능:
+1.11%
1개월 성능:
-7.01%
6개월 성능:
-17.33%
1년 성능:
+25.86%
1일 변동 폭
$7.02
$7.325
1주일 범위
$7.02
$7.63
52주 변동 폭
$4.79
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.30 | 1.15B | 61.10M | -138.36M | -90.59M | -1.35 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix at BioConnect: Strategic Advances in Wet AMD Treatment By Investing.com - Investing.com Canada
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewswire
Ocular Therapeutix CEO to Present at RBC, Mizuho, and Top Healthcare Conferences: Key Dates for Investors - Stock Titan
The Manufacturers Life Insurance Company Sells 2,399 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Transcript : Ocular Therapeutix, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Hsbc Holdings PLC Buys 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Tower Research Capital LLC TRC Has $76,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for OCUL - Defense World
William Blair Brokers Decrease Earnings Estimates for OCUL - Defense World
Analysts Offer Predictions for OCUL FY2026 Earnings - Defense World
Ocular Therapeutix at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com India
Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates - simplywall.st
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst Downgrade - Defense World
Analyst Expectations For Ocular Therapeutix's Future - Benzinga
Ocular Therapeutix (OCUL) Maintained as Buy by Needham, Price Ta - GuruFocus
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations - Yahoo
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
Ocular Therapeutix Inc earnings missed by $0.09, revenue fell short of estimates - Investing.com Nigeria
OCUL's Financial Position: Cash Reserves Expected to Sustain Unt - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) M - GuruFocus
Raymond James maintains strong buy on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix™ Reports First Quarter 2025 Results and Busin - GuruFocus
Ocular Therapeutix stock tumbles as Q1 results miss estimates By Investing.com - Investing.com Canada
Ocular Therapeutix stock tumbles as Q1 results miss estimates - Investing.com
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix (OCUL) Advances Retinal Therapy Pipeline Amid Revenue Miss | OCUL Stock News - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) Misses Estimate, Revenue Falls Short at $10.7 Million - GuruFocus
Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls - marketscreener.com
Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Net Loss $0.38 a Share, vs. FactSet Est of $0.29 Loss - marketscreener.com
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights - The Manila Times
Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights - TradingView
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BRIEF-Ocular Therapeutix Q1 EPS USD -0.38 Vs. IBES Estimate USD -0.29 - TradingView
Ocular Therapeutix Earnings: $349M War Chest Powers AXPAXLI Trials as FDA Backs NPDR Program - Stock Titan
Ocular Therapeutix (OCUL) Projected to Post Earnings on Monday - Defense World
Wells Fargo & Company MN Has $634,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Kn - GuruFocus
Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical - openPR.com
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):